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Abstract. Toxic effects from 13 li_meta_iodobenzylguanidine 
(131I-MIBG) treatments of neuroblastoma in six patients 
were recorded. The toxicity was largely confined to the he- 
matologic system where circulating leukocytes and platelets 
regularly declined after each dose of 13q-MIBG; the values 
reached nadirs between three and seven weeks and recov- 
ered slowly over subsequent weeks. Prior bone marrow 
transplantation and infiltration of bone marrow by neurob- 
lastoma appeared to make the hematologic system more 
vulnerable to the radiation. Dosimetry revealed greater ab- 
sorbed radiation by the whole body than by the blood and 
bone marrow. These observations are explained by a rela- 
tively rapid exit of 131I-MIBG from the blood to other 
tissues (but not to the bone marrow). Since treatment of 
an aggressive and lethal tumor such as neuroblastoma 
should be pushed to a degree of toxicity, careful dosimetry 
in each case will be necessary as a guide to reach the point 
of maximally tolerable toxicity. 
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The radiopharmaceutical 13q-meta-iodobenzylguanidine 
(131I-MIBG), concentrates in some cancers to a degree that 
therapeutic radiation is imparted. Reports describe benefi- 
cial effects from treatments using 13 I I_MIBG for malignant 
pheochromoeytoma (Sisson et al. 1984; Hoefnagel et al. 
1987), neuroblastoma and related tumors (Hoefnagel et al. 
1987). Untoward responses to this form of therapy appear 
to be modest and well tolerated (Sisson et al. 1984; Hoefna- 
gel et al. 1987). 
Although tumors have diminished after administrations 
of 131I-MIBG, complete remissions have been uncommon 
and but a few months in duration, this has been particularly 
so in cases of neuroblastoma (Hoefnagel et al. 1987). It 
is possible that larger doses of 13~I-MIBG will be more 
effective, but such an increase incurs the risk of toxic reac- 
tions. 
Because neuroblastoma is a relatively common tumor 
in children, and because it is aggressive, and in stage IV 
almost always lethal, some untoward reactions from thera- 
py are acceptable. Indeed, chemotherapy is ordinarily ad- 
ministered to patients with neuroblastoma to a point where 
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toxicity is evident; treatment with maximally tolerable 
doses is the rule. To obtain the best chance for success, 
a new form of treatment, such as 131I-MIBG, should prob- 
ably be administered under the same rule. 
We report here the toxic responses to therapeutic doses 
of 131I-MIBG in patients with neuroblastoma. The major 
toxicity has been in the hematologic system and appears 
to relate to absorbed radiation for the whole body rather 
than that for the blood. 
Materials and methods 
Patients .  The patients were referred to the University of 
Michigan Medical Center for treatment of neuroblastoma 
by 131I-MIBG. In each case the neuroblastoma was in stage 
IV and had previously been treated with one or more che- 
motherapeutic protocols. Eight patients had dosimetry 
measurements, however, I patient was excluded because 
an insufficient number of blood samples were obtained to 
enable calculation of absorbed radiation to her blood, and 
another patient was not included because his marrow func- 
tion was already greatly diminished by the neuroblastoma 
and prior chemotherapy (platelets 30 000/mm 3) so that toxi- 
city to the bone marrow from aalI-MIBG could not be 
judged. Thus, six patients with neuroblastoma formed the 
basis for this study. Patients 4 and 5 received 2 treatments, 
and patient 6 received 3 treatments with 131I-MIBG, but 
complete data were available for only the 3rd treatment. 
All other patients received one treatment. Patient 1 devel- 
oped infiltration of her bone marrow by neuroblastoma 
within weeks of treatment with 131I-MIBG, and patients 
2 and 5 had undergone bone marrow transplantation. 
M e thods .  1, II_MIBG was synthesized for diagnostic studies 
and therapy by methods previously described (Sisson et al. 
1984; Mangner et al. 1982). Diagnostic doses of 131I-MIBG 
were 1 mCi (37 MBq) per 1.73 m 2 of body surface area 
but did not exceed 1 mCi. Both diagnostic and therapeutic 
doses were infused intravenously over 90 min except in pa- 
tient 5 whose diagnostic and therapeutic doses were infused 
over 24 h. 
Whole body dosimetry in children was calculated from 
measurements obtained at 2 m with a flat field scintillation 
probe containing a 2 x 2 in. sodium iodide crystal and aimed 
at the xiphoid. For adult sized patients the distance from 
probe to patient was 2.5 m. Readings were obtained from 
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Table 1. Patient characteristics and absorbed radiation from 131I-MIBG 
Patient Age Sex Body Dose 
(years) weight (mCi) 
(kg) 
Absorbed Radiation (Rads or cGy) 
Blood Whole body 
Beta Total Beta  Gamma Total 
Retention 
at 48 h 
(mCi or 
MBq x 37) 
t 3.5 F 14.0 139 36 
2 6 F 19.8 203 25 
3 6 M 19.8 200 14 
4 2 F 1st 11.4 132 33 
2nd 11.9 157 24 
5 6 F 1st 20.0 212 a 
2nd 20.6 199 28 
6 25 M 56.6 220 17 
ll0 156 74 231 33 
88 120 63 183 37 
76 118 62 180 44 
84 119 51 170 21 
80 129 56 185 24 
a 87 45 132 b 42 
73 85 45 130 b 32 
59 61 42 103 46 
a Blood absorbed radiation not determined 
b Whole body absorbed radiation measured from therapeutic dose 
for diagnostic doses 
because whole body counts not done and urine collection incomplete 
both the anterior and posterior aspects of the patients to 
give a geometric mean. Body counts were obtained immedi- 
ately following the infusion of the diagnostic dose of t3~I- 
MIBG, 3 h after the infusion, and then daily for at least 
4 days. An exception was patient 5 who had whole body 
radiation measured from her 2 therapeutic doses; body 
counts were not obtained from the diagnostic doses, and 
measurements based on urinary excretion rates of the diag- 
nostic doses were vitiated by incomplete collections of ur- 
ine. Calculation of whole body absorbed radiation dose 
was by a method previously described and modified (Leeper 
and Shimaoka 1980; Nostrand etal. 1986; Benua et al. 
1962). In each patient, the whole body retention of tracer 
doses was compared with that obtained from a portable 
ionization chamber survey meter (Cutie pie) which gave 
readings of whole body radioactivity after the therapy dose 
(Thomas et al. 1980). 
The absorbed dose of beta radiation in the whole body 
was calculated from the activity retained at the serial points 
of measurement assuming a uniform distribution of 131[ 
throughout the body (Berlin 1968). Errors arise because 
the ~3XI-MIBG is not uniformly distributed in patients, but 
these calculations give the best index available for compar- 
ision among patients. Total absorbed beta dose was ob- 
tained from the area below the individual data points. Tu- 
mor concentration of the radiopharmaceuticals was less 
than 2% of the dose, and therefore reciprocity of radiation 
from tumor to body was not considered. 
Blood samples were obtained for counting radioactivity 
at the times of whole body counting. Absorbed beta radia- 
tion was calculated from the concentration of activity in 
blood over time, and the trapezoid areas determined for 
each time interval (Leeper and Shimaoka 1980; Nostrand 
et al. 1986; Benua et al. 1962). Absorbed gamma radiation 
by the blood was considered to be the same as that of 
the whole body. In three patients, bone marrow was aspir- 
ated for counting at the time the blood sample was obtained 
one day after the infusion of 13~I-MIBG. The marrow as- 
pirates contained no neuroblastoma cells on morphologic 
examination. Each marrow specimen was diluted by some 
blood, but, when the radioactivity per unit volume was 
compared with that in blood, a trend of more or less radio- 
activity could be ascertained. 
Hematologic indices were obtained at one to two week 
intervals in the children, and at two to three month intervals 
in the adult patient. 
Results  
Excretion of 131I-MIBG was relatively rapid so that no 
patient retained more then 46 mCi (1.7 GBq) by 48 h after 
dose administration (Table 1). Absorbed radiation by the 
whole body from 131I-MIBG was invariably greater than 
that by the blood (Table 1). Since gamma radiation to the 
blood was considered to be the same as that to the body, 
the differences between absorbed doses to the whole body 
and to the blood were most striking when the respective 
beta radiations were compared. When adsorbed radiation 
predicted from the diagnostic doses of 13~I-MIBG was ex- 
pressed as ratios of beta dose to blood divided by beta 
radiation to whole body, values were below 0.36 both at 
24 h and for the total therapy (Table 2). Similar blood/body 
radiation ratios probably occurred when therapeutic doses 
were given since, following treatment with ~3~I-MIBG, the 
total absorbed radiation to the body was similar to that 
predicted from the diagnostic dose (Table 2). 
Although the aggregate body tissues received more radi- 
ation than blood from 131I-MIBG, bone marrow was not 
a site of sequestration of this radiopharmaceutical. Marrow 
aspirates from three patients contained quantities of radio- 
activity similar to those in the respective blood specimens 
obtained at the same time (Table 2). 
Since rates of excretion of 131I-MIBG were similar 
among the patients, the absorbed radiation was, for the 
most part, determined by the dose and body weight of the 
individual (and volume of distribution of the 131I). Thus, 
patient 6, an adult weighing 56.6 kg, received only 50% 
of the whole body radiation of patient 2, a child weighing 
19.8 kg; yet, these 2 patients received similar doses of ~3~I- 
MIBG, 220 and 203 mCi (8.1 and 7.5 GBq), respectively. 
Except in patient 6, 131I-MIBG therapies were asso- 
ciated with a substantial reduction in the circulating plate- 
Table 2. Relationships of absorbed radiation doses from 13 II_MIBG 
Pataent Blood/ Beta dose: Whole body 
marrow blood/whole body dosimetry 
treatment dose/ 





0.35 0.23 0.76 
0.31 0.21 0.93 
0.14 0.12 0.78 
0.35 0.28 0.80 
0.23 0.19 0.72 
0.28 0.32 - 
0.27 0.28 0.93 
a Total whole body absorbed radiation calculated from diagnostic 
dose for treatment given: and directly from treatment dose by 
bedside dosimeter 
lets (Table 3); the nadir, occurring at 6 weeks, was fre- 
quently less than 30% of  the pretherapeutic values. Recov- 
ery occurred over many weeks (Fig. 1). This relative decline 
in platelets was generally greater than that of  the leuko- 
cytes, although the circulating white cells were appreciably 
reduced in all neuroblastoma patients except patient 6. At  
the nadir, the differential count was generally unchanged 
in the leukopenic specimens. However, patient 2 exhibited 
both a decline in total leukocytes and a selective neutro- 
penia; her absolute neutrophil count at nadir was 384/mm 3. 
Recovery from leukopenia also required weeks but was usu- 
ally more rapid and complete than that for the thrombocy-  
topenia (Fig. 1). 
Patients were arranged in the tables according to ab- 
sorbed dose for the whole body, but the changes in the 
circulating leukocytes and platelets did not  follow this 
order. There was a relatively greater decline in both leuko- 
cytes and platelets in patients 1, 2 and 5 than in the others 
(Table 3). Possibly the vulnerability of  the hematologic sys- 
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tern to radiation from 13aI-MIBG in these patients related 
to the marrow transplantation in patients 1 and 5 and to 
the marrow infiltration by neuroblastoma that occurred 
shortly after treatment in patient 2. The virtual absence 
of  change in the leukocytes and platelets in patient 6 prob- 
ably reflected the lower absorbed radiation dose in this 
adult man. 
Comparison of  the response in patient 4, whose marrow 
was normal, with that in patient 5, who had a marrow 
transplantation, is shown in Fig. 1. In neither patient was 
recovery of  thrombocytopenia complete within 15 weeks 
after the initial treatment with a3~I-MIBG. The nadir of  
leukocytes was reached slightly earlier than that of  platelets. 
No  patient developed infection or bleeding in associa- 
tion with the decline in leukocytes and platelets. Patient 
4 exhibited elevation in transminase enzyme values for some 
weeks after each therapy, probably reflecting some radia- 
tion hepatitis. The only other complication attributable to 
the therapy with 131I-MIBG was nausea and occasional 
vomiting for a day or two. Routine tests showed no abnor- 
mality in kidney function, and clinical appraisals found no 
disturbances in lung or heart. Concentrations of  serum 
TSH, T4 cortisol and results of  testing autonomic function 
(Sisson et al. 1984) showed no change. 
Discuss ion  
Treatments with substantial doses of  a radiopharmaceutical 
such as 131I-MIBG, not unexpectedly, were associated with 
depression of  circulating leukocytes and platelets, but the 
absorbed dose to the blood was less than that calculated 
for the whole body. Thus, based on the above data, toxicity 
to the bone marrow from a3aI-MIBG will probably be more 
accurately predicted by measurements of  radiation to the 
whole body than those of  the blood. Indeed, if 200 rads 
to the blood were to be the limiting factor (Leeper and 
Shimaoka 1980), some of  our patients would have received 
over 500 mCi (18.5 GBq) in a single dose, a treatment 
that would probably have been lethal. 
It is not  clear how the bone marrow receives so much 
radiation. From the samples o f  marrow obtained, the 
Table 3. Changes in circulating leukocytes and platelets following 131I-MIBG 
Patient Whole body Marrow 
total radiation status 
(RADS or cGy) 





Platelets (1000/mm 3) 
Before Nadir 
Rx 
Fraction a Intervalb 
(weeks) 
1 231 Infiltration ° 6.7 2.6 
2 ] 82 Transplant 5.1 t .6 
3 180 Normal 4.6 3.5 
4 170 Normal 5.5 3.6 
185 4.9 2.8 
5 132 Transplant 5.2 2.5 
130 4.7 1.6 








0.81 9 d 
235 70 0.30 5 
201 52 0.26 5 
384 174 0.45 4-5 
287 129 0.45 3-5 
253 142 0.56 4 
410 120 0.29 5-6 
267 63 0.24 6 
300 291 0.97 9 
a Nadir/before Rx values 
b Interval between treatment and nadir 
Infiltration by neuroblastoma wathin weeks of therapy 
a First post treatment sample at nine weeks 
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Fig. 1A, B. Circulating leukocyte and platelet values over time after 
treatments with 13~I-MIBG. A Patient 4 who had a normal bone 
marrow. The treatments with 132 rnCi (4.9 GBq) and 157 mCi 
(5.8 GBq) 13JI-MIBG imparted respectively, 170 and 185 rads 
(cGy) to the body. B Patient 5 who had a bone marrow transplanta- 
tion. The treatments with 212 mCi (7.8 GBq) and 199 mCi (7.4 
GBq) 131I-MIBG delivered, respectively, 132 and 130 rads (cGy) 
to the body, yet the declines in leukocytes and platelets were more 
marked than in A 
amount  of  radioact ivi ty appears  about  the same or less 
than that  in blood,  at least at  24 h after the ~31I-MIBG 
has been administered. Grea ter  diffusion into the marrow 
at later times is possible but  seems unlikely. Even at 24 h 
the absorbed dose to the body is greater than that  to the 
blood indicating that  exit of  ~3~I-MIBG from blood to tis- 
sue is a lready taking place, but  the tissues that  sequester 
131I-MIBG do not  include the bone marrow.  On the other 
hand, since 131I-MIBG is concentrated in platelets (Feld- 
man  et al. 1984), it is possible that  certain marrow precursor  
cells, such as megakaryocytes,  can selectively bind 131I- 
M I B G  to a level that  would cause injury to these cells, 
but  the quant i ty  would not  be apparent  in an assay of  
overall bone marrow radioactivity.  
The toxicity of  t31I-MIBG was apparent ly  made more  
prominent  by bone marrow t ransplanta t ion  and by subse- 
quent infi l trat ion of  marrow by neuroblastoma.  All  patients 
with neuroblas toma had received multiple courses of  che- 
motherapy  which may  also have made the bone mar row 
more  vulnerable to the effects of  radiat ion.  
Treatments  of  cancers by radiopharmaceut icals  will 
p robably  follow the experience gained with chemotherapy.  
F o r  aggressive and lethal neoplasms such as neuroblas-  
toma, opt imal  effects will not  be at tained unless the treat-  
ment  is pushed to toxic levels. Mos t  often the limiting toxi- 
city from radiopharmaceut icals  will be depression of  the 
bone marrow,  and, as demonstra ted in this report,  measure- 
ments of  absorbed doses of  radiat ion will be required to 
determine the limiting guidelines for each new agent. 
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